Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Garuda, Indofood Sukses, Kalbe Farma: Indonesian Equity Preview

Don't Miss Out —
Follow us on:

May 24 (Bloomberg) -- Shares of the following companies may have unusual moves in Indonesian trading. Stock symbols are in parentheses, and share prices are as of the previous close.

The Jakarta Composite index fell 1 percent to 3,981.58.

Energy companies: Crude oil for July delivery dropped 2.1 percent to $89.90 a barrel in New York yesterday, erasing gains through 2011. The contract was last at $90.79 in after-hours trading. PT Medco Energi Internasional (MEDC IJ), Indonesia’s biggest listed oil company, lost 1.6 percent to 1,900 rupiah and PT Energi Mega Persada (ENRG IJ), the second largest, sank 5.9 percent to 161 rupiah.

PT Garuda Indonesia (GIAA IJ): The national flag carrier signed a preliminary agreement with Accor SA, Europe’s biggest hotel operator, to help attract more passengers, Bisnis Indonesia reported, citing Garuda President Director Emirsyah Satar. The agreement will allow Accor’s members to buy Garuda tickets at discounts, the report said. Garuda declined 1.4 percent to 710 rupiah.

PT Indofood Sukses Makmur (INDF IJ): The parent company of Indonesia’s largest instant noodle maker will sell 2 trillion rupiah ($216 million) of five-year bonds with a coupon rate of 7.25 percent this month, it said in a statement published in Bisnis Indonesia. Indofood rose 1.1 percent to 4,775 rupiah.

PT Kalbe Farma (KLBF IJ): Indonesia’s biggest drug maker set aside between 500 billion rupiah and 1 trillion rupiah to finance acquisitions of pharmaceutical and nutritional product makers, the Jakarta Post reported, citing Director Vidjongtius. Kalbe also plans a stock split with a ratio of five-for-one, the report said. The stock was unchanged at 3,900 rupiah.

To contact the reporter on this story: Berni Moestafa in Jakarta at bmoestafa@bloomberg.net

To contact the editor responsible for this story: Darren Boey at dboey@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.